Compare AbCellera Biologics Inc (ABCL) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Manulife Financial Corporation — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Manulife Financial Corporation trades at $41 (market cap $68.99B). The key difference: Manulife Financial Corporation is far larger — about 29.4× AbCellera Biologics Inc's market cap, and Manulife Financial Corporation pays a 3.22% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MFC | |
|---|---|---|
Market Cap | $2.35B | $68.99B |
Sector | Health | Financials |
52-Week High | $8.12 | $41.40 |
52-Week Low | $2.78 | $29.90 |
Enterprise Value | $1.99B | $65.55B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Manulife Financial (MFC) trades at $41.40, up 0.53% today, with a bullish technical signal from moving averages and strong analyst support (57% buy ratings). Recent Q1 2026 earnings missed expectations, but revenue grew to $53.01B in 2025, with net income of $5.78B. The company maintains a solid dividend, with a $0.49 payment scheduled for June 2026, and has demonstrated consistent operational cash flow growth, reaching $32.11B in 2025.
MFC's outlook is positive due to its AI initiatives and Asia growth, but risks include regulatory scrutiny and Q1 earnings miss. The stock's P/E of 16.92 and ROE of 13.14% suggest reasonable valuation, though investors should monitor debt levels and competitive pressures in insurance markets for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
